AstraZeneca’s U.S. Trial Remains on Hold Pending FDA Review

(Bloomberg) -- AstraZeneca Plc’s Covid-19 vaccine study remains paused in the U.S. pending a regulatory review of an incident in which a U.K. participant became ill, federal officials said.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.